Published in Mykosen on November 01, 1987
In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol (1988) 2.88
Candida albicans strain delineation. Clin Microbiol Rev (1990) 1.90
Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol (1999) 1.96
Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol (1998) 1.70
Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol (1999) 1.69
The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol (2006) 1.55
Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br J Dermatol (2002) 1.42
[Pyoderma]. Hautarzt (1998) 1.37
Influence of serum protein binding on the in vitro activity of anti-fungal agents. Infection (1996) 1.23
Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol (2004) 1.19
Late cutaneous schistosomiasis representing an isolated skin manifestation of schistosoma mansoni infection. Dermatology (2000) 1.19
[Normal pH value of human skin]. Hautarzt (1986) 1.16
Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes. Infect Immun (1993) 1.14
Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study. Antimicrob Agents Chemother (1991) 1.13
Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J Clin Microbiol (1995) 1.07
Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. J Invest Dermatol (2000) 1.07
Characterisation of penicillinase producing gonococci isolated in Munich, 1981-6. Genitourin Med (1988) 1.02
1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol (2001) 0.99
[Morphologic variants of genital ulcer caused by Haemophilus ducreyi]. Hautarzt (1989) 0.99
Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. J Am Acad Dermatol (1990) 0.98
The role of vitamin E in normal and damaged skin. J Mol Med (Berl) (1995) 0.97
The role of Candida albicans secreted aspartic proteinase in the development of candidoses. J Mol Med (Berl) (1996) 0.96
Antimicrobial susceptibility testing of dermatophytes--comparison of the agar macrodilution and broth microdilution tests. Chemotherapy (1998) 0.96
Reconstructed epidermis versus human and animal skin in skin absorption studies. Toxicol In Vitro (2005) 0.95
Anti-microbial and -inflammatory activity and efficacy of phytosphingosine: an in vitro and in vivo study addressing acne vulgaris. Int J Cosmet Sci (2007) 0.95
Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts. Int J Antimicrob Agents (2001) 0.95
Cefodizime penetration into skin suction blister fluid following a single intravenous dose. Eur J Clin Pharmacol (1986) 0.95
Onychomycosis. Mycoses (2007) 0.94
The KEX2 gene of Candida glabrata is required for cell surface integrity. Mol Microbiol (2001) 0.94
Aquarium dermatitis: cercarial dermatitis in an aquarist. Dermatology (1998) 0.93
Actinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol (2004) 0.92
Plasmid content and protein I serovar of non-penicillinase-producing gonococci isolated in Munich. Epidemiol Infect (1988) 0.92
In vivo expression and localization of Candida albicans secreted aspartyl proteinases during oral candidiasis in HIV-infected patients. J Invest Dermatol (1999) 0.91
The use of systemic antimycotics in dermatotherapy. Eur J Dermatol (2000) 0.91
Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release (2005) 0.90
Preputial abscesses caused by beta-lactamase-producing gonococci. Cutis (1985) 0.90
Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete's foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol (2006) 0.89
Liposomes: a drug carrier system for topical treatment in dermatology. Crit Rev Ther Drug Carrier Syst (1994) 0.89
Phospholipases of Candida albicans. Mycoses (2001) 0.88
Influence of repeated washings with soap and synthetic detergents on pH and resident flora of the skin of forehead and forearm. Results of a cross-over trial in health probationers. Acta Derm Venereol (1987) 0.88
RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie (2005) 0.88
In vitro activity of eight antimicrobial agents against non-penicillinase-producing gonococci isolated in Munich. Genitourin Med (1988) 0.87
Persistent oral candidosis by non-albicans Candida strains including Candida glabrata in a human immunodeficiency virus-infected patient observed over a period of 6 years. Mycoses (1999) 0.87
Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target (2002) 0.87
HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study. Mycoses (1999) 0.87
Diffusion tensor imaging in acquired blind humans. Neurosci Lett (2006) 0.87
Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. Eur J Clin Pharmacol (1985) 0.87
Repeated exposition to subinhibitory concentrations of antibiotic in vitro readily decreases susceptibility of Neisseria gonorrhoeae to rifampicin, but not to new cephalosporins and penicillin G. Chemotherapy (1984) 0.86
Management of onychomycoses. Drugs (1999) 0.86
Susceptibility of Neisseria gonorrhoeae to ceftizoxime in vitro and in vivo. Chemotherapy (1984) 0.86
Prevalence of gonococci lacking the 2.6 megadalton cryptic plasmid. Lancet (1987) 0.85
Does cantharides blister fluid provide access to the peripheral compartment? Eur J Clin Pharmacol (1982) 0.85
Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol (2005) 0.85
Ketoconazole concentrations in human skin blister fluid and plasma. Int J Clin Pharmacol Ther Toxicol (1984) 0.85
Comparative efficacy and safety of bifonazole 1% cream and the corresponding base preparation in the treatment of seborrhoeic dermatitis. Mycoses (1994) 0.84
Effect of iron limitation on protein composition and ultrastructure of Haemophilus ducreyi. FEMS Microbiol Lett (1990) 0.84
Mechanisms of skin adherence, penetration and tissue necrosis production by Haemophilus ducreyi, the causative agent of chancroid. Acta Derm Venereol Suppl (Stockh) (1992) 0.84
[Antimicrobial effects of in vitro-simulated ketoconazole-cantharidin blister fluid levels on candida albicans]. Mykosen (1986) 0.84
Evaluation of cefotetan in uncomplicated gonorrhea. Dermatologica (1986) 0.84
Molecular and phenotypic identification of the yeast pathogen Candida dubliniensis. J Mol Med (Berl) (2000) 0.83
Innate immune receptors on neutrophils and their role in chronic lung disease. Eur J Clin Invest (2009) 0.83
Reflectance confocal microscopy in the diagnosis of partially and completely amelanotic melanoma: report on seven cases. J Eur Acad Dermatol Venereol (2012) 0.83
Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol (2004) 0.83
Sunscreens - which and what for? Skin Pharmacol Physiol (2005) 0.83
Glucocorticoid entrapment into lipid carriers--characterisation by parelectric spectroscopy and influence on dermal uptake. J Control Release (2004) 0.83
Dubowitz syndrome: atopic dermatitis, low birth weight dwarfism and facial dysmorphism. Dermatologica (1990) 0.83
Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis. Skin Pharmacol (1992) 0.83
Immunohistochemical investigations of genital ulcers caused by Haemophilus ducreyi. Int J STD AIDS (1997) 0.83
Liposomes for atopic dry skin: the rationale for a promising approach. Clin Investig (1993) 0.82
Absence of extracellular enzyme activity and cytotoxicity in cell-free culture filtrates of Haemophilus ducreyi. Microb Pathog (1991) 0.82
Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging. Skin Pharmacol Physiol (2004) 0.82
In vitro investigations on the mode of action of the hydroxypyridone antimycotics rilopirox and piroctone on Candida albicans. Mycoses (2006) 0.82
The secreted aspartic proteinases as a new target in the therapy of candidiasis. Curr Drug Targets (2002) 0.82
In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther (1995) 0.82
Human plasma and skin blister fluid levels of griseofulvin after its repeated administration. Eur J Clin Pharmacol (1985) 0.82
Folliculitis decalvans. Long-lasting response to combined therapy with fusidic acid and zinc. Acta Derm Venereol (1992) 0.82
Interaction of cultured human keratinocytes with liposomes encapsulating silver sulphadiazine: proof of the uptake of intact vesicles. Br J Dermatol (1996) 0.82
Distribution of auxotypes and correlation to antibiotic susceptibility of 169 recent clinical Neisseria gonorrhoeae isolates from Munich. Arch Dermatol Res (1983) 0.82
Intraindividual variations of 8-methoxypsoralen plasma levels. Arch Dermatol Res (1982) 0.82
Fifty-kDa hyaluronic acid upregulates some epidermal genes without changing TNF-α expression in reconstituted epidermis. Skin Pharmacol Physiol (2011) 0.81
Soluble interleukin-2 receptors in serum and urine of patients with chancroid and their response to therapy. Int J STD AIDS (1990) 0.81
Antifungal susceptibility testing with dermatophytes. Mycoses (1992) 0.81
The concept of the acid mantle of the skin: its relevance for the choice of skin cleansers. Dermatology (1995) 0.81
Glucocorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacol Physiol (2005) 0.81
Comparative therapeutic and toxic effects of different povidone iodine (PVP-I) formulations in a model of oral candidosis based on in vitro reconstituted epithelium. J Drug Target (2001) 0.81
[Coincidence of multiple cylindroma and trichoepitheliomas (Brooke-Spiegler-Syndrome)]. Hautarzt (1982) 0.80
Use of a transport medium in the search for Salmonella carriers--is it worthwhile? Med Microbiol Immunol (1980) 0.80
Plasma, cantharides blister fluid, and suction blister fluid levels of ceftizoxime after single intramuscular application for gonorrhea. Int J Clin Pharmacol Ther Toxicol (1984) 0.80
Current state of three-dimensional characterisation of antifungal targets and its use for molecular modelling in drug design. Int J Antimicrob Agents (2005) 0.80
Toxicity and antimicrobial activity of a hydrocolloid dressing containing silver particles in an ex vivo model of cutaneous infection. Skin Pharmacol Physiol (2004) 0.80
The 15-domain serine proteinase inhibitor LEKTI: biochemical properties, genomic organization, and pathophysiological role. Eur J Med Res (2002) 0.80
Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound. Acta Derm Venereol (1992) 0.80
[Cephalosporin allergy and cephalosporin-penicillin cross allergies with special reference to venereologic therapy of severe anaphylactic reactions]. Hautarzt (1984) 0.80
Successful treatment of griseofulvin-resistant tinea capitis in infants. Mycoses (1995) 0.80
Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age. Pharmazie (1999) 0.80
Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis. Skin Pharmacol Physiol (2008) 0.80
The Phenion full-thickness skin model for percutaneous absorption testing. Skin Pharmacol Physiol (2009) 0.80
Nicotinamide - biologic actions of an emerging cosmetic ingredient. Int J Cosmet Sci (2005) 0.80
Tinea capitis: ringworm of the scalp. Mycoses (2007) 0.80
Different isoforms of secreted aspartyl proteinases (Sap) are expressed by Candida albicans during oral and cutaneous candidosis in vivo. J Med Microbiol (2001) 0.80
Identification of dermatophytes by Fourier transform infrared spectroscopy (FT-IR). Mycoses (1999) 0.79